Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival

Blood

Volumn 119, Issue 24, 2012, Pages 5850-5858

  Debrincat, Marlyse A ^a,b   Josefsson, Emma C ^a,b   James, Chloé ^a,b,f,g,h   Henley, Katya J ^a   Ellis, Sarah ^c   Lebois, Marion ^a   Betterman, Kelly L ^d   Lane, Rachael M ^a   Rogers, Kelly L ^a   White, Michael J ^a,b   Roberts, Andrew W ^a,b   Harvey, Natasha L ^d,e   Metcalf, Donald ^a,b   Kile, Benjamin T ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d CENTRE FOR CANCER BIOLOGY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h Bordeaux Segalen University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CELL COUNT; CELL DEATH; CELL LINEAGE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; EOSINOPHIL COUNT; FETUS; FETUS LIVER; GENE DELETION; HEMATOCRIT; LETHALITY; LYMPHOCYTE COUNT; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MONOCYTE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE VOLUME; THROMBOCYTOPOIESIS;

EID: 84862496374     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-398834     Document Type: Article

References (41)

1. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317(5845):1767-1770. (Pubitemid 47461844)
2. Italiano J, Lecine P, Shivdasani R, Hartwig J. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999;147(6):1299-1312. (Pubitemid 30012814)
3. Becker RP, De Bruyn PP. The transmural passage of blood cells into myeloid sinusoids and the entry of platelets into the sinusoidal circulation; a scanning electron microscopic investigation. Am J Anat. 1976;145(2):183-205.
4. Leeksma C, Cohen J. Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate. Nature. 1955;175(4456):552-553.
5. Ault KA, Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol. 1995;23(9):996-1001.
6. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
7. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128(6):1173-1186. (Pubitemid 46427871)
8. Kodama T, Takehara T, Hikita H, et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology. 2010;138(7):2487-2498.
9. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med. 2011;208(10):2017-2031.
10. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677-681. (Pubitemid 40825512)
11. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
12. Dasgupta SK, Argaiz ER, Mercado JE, et al. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010;50(10):2167-2175.
13. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009;114(3):663-666.
14. Vogler M, Hamali HA, Sun XM, et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood. 2011;117(26):7145-7154.
15. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951. (Pubitemid 46655455)
16. Schoenwaelder SM, Jarman KE, Gardiner EE, et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118(6):1663-1674.
17. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-496.
18. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159.
19. Dzhagalov I, St John A, He Y. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. 2007;109(4):1620-1626. (Pubitemid 46239596)
20. Opferman J, Iwasaki H, Ong C, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101- 1104. (Pubitemid 40262114)
21. Opferman J, Letai A, Beard C, Sorcinelli M, Ong C, Korsmeyer S. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671-676. (Pubitemid 38009376)
22. Rucker EB, 3rd Dierisseau P, Wagner KU, et al. Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. Mol Endocrinol. 2000;14(7):1038-1052.
23. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506. (Pubitemid 46239582)
24. Alexander W, Roberts A, Nicola N, Li R, Metcalf D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996;87(6):2162-2170.
25. Kruse EA, Loughran SJ, Baldwin TM, et al. Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc Natl Acad Sci U S A. 2009;106(33):13814-13819.
26. Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest. 1964;43:843-855.
27. Dowling MR, Josefsson EC, Henley KJ, Hodgkin PD, Kile BT. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood. 2010;116(10):1776-1778.
28. Bertozzi CC, Schmaier AA, Mericko P, et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood. 2010;116(4):661-670.
29. Carramolino L, Fuentes J, Garcia-Andres C, Azcoitia V, Riethmacher D, Torres M. Platelets play an essential role in separating the blood and lymphatic vasculatures during embryonic angiogenesis. Circ Res. 2010;106(7):1197-1201.
30. Matsumura G, Sasaki K. The ultrastructure of megakaryopoietic cells of the yolk sac and liver in mouse embryo. Anat Rec. 1988;222(2):164-169.
31. Tober J, Koniski A, McGrath KE, et al. The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis. Blood. 2007;109(4):1433-1441. (Pubitemid 46239574)
32. Nijhawan D, Fang M, Traer E, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003;17(12):1475-1486. (Pubitemid 36734705)
33. Houwerzijl E, Blom N, van der Want J, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2):500-506. (Pubitemid 38140080)
34. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood. 2005;105(9):3472-3479. (Pubitemid 40628188)
35. Zauli G, Catani L, Gibellini D, et al. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol. 1996;92(3):711-717. (Pubitemid 26076772)
36. Houwerzijl EJ, Blom NR, van der Want JJL, Vellenga E, de Wolf JTM. Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 2006;20(11):1937-1942. (Pubitemid 44614881)
37. Liu ZJ, Italiano J Jr, Ferrer-Marin F, et al. Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. Blood. 2011;117(15):4106-4117.
38. Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011;10(12):2340-2349.
39. Leber B, Geng F, Kale J, Andrews DW. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med. 2010;12:e28.
40. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7(12):989-1000.
41. Petros AM, Huth JR, Oost T, et al. Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett. 2010;20(22):6587-6591.